$EMMA
Emmaus Life Sciences, Inc. Stock $emma

$emma Overview Financials Valuation SEC Filings Company Website

2013 Form 10-K Financial Statement

#000114420413068769 Filed on December 23, 2013

Income Statement

Concept	2013	2012 Q3	2012
Revenue	$130.9K	$30.00K	$120.0K
YoY Change	9.08%	-85.71%	-84.0%
Cost Of Revenue	$140.0K	$20.00K	$130.0K
YoY Change	7.69%	-50.0%	-13.33%
Gross Profit	-$10.00K	$0.00	-$20.00K
YoY Change	-50.0%	-100.0%	-103.33%
Gross Profit Margin	-7.64%	0.0%	-16.67%
Selling, General & Admin	$2.902M	$860.0K	$3.935M
YoY Change	-26.27%	-36.3%	-28.45%
% of Gross Profit
Research & Development	$1.290M	$170.0K	$850.0K
YoY Change	51.76%	13.33%	-7.61%
% of Gross Profit
Depreciation & Amortization	$13.00K	$10.00K	$18.80K
YoY Change	-30.85%		88.0%
% of Gross Profit
Operating Expenses	$4.332M	$1.040M	$4.921M
YoY Change	-11.98%	-30.67%	-23.35%
Operating Profit	-$4.201M	-$1.040M	-$4.806M
YoY Change	-12.59%	-21.8%	-17.42%
Interest Expense	-$1.288M	$5.290M	-$4.123M
YoY Change	-68.76%	812.07%	457.19%
% of Operating Profit
Other Income/Expense, Net	-$6.687M	$10.00K	$1.892M
YoY Change	-453.51%	-50.0%	-673.18%
Pretax Income	-$10.89M	$4.260M	-$2.914M
YoY Change	273.57%	-257.78%	-67.14%
Income Tax	$800.00	$0.00	$1.900K
% Of Pretax Income		0.0%
Net Earnings	-$10.91M	$4.100M	-$3.407M
YoY Change	220.17%	-251.85%	-61.59%
Net Earnings / Revenue	-8332.62%	13666.67%	-2839.0%
Basic Earnings Per Share	-$0.14		-$1.81
Diluted Earnings Per Share	-$0.14	$4.497B	-$1.81
COMMON SHARES
Basic Shares Outstanding	75.80M shares		1.888M shares
Diluted Shares Outstanding	75.80M shares		1.888M shares

Balance Sheet

Concept	2013	2012 Q3	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.270M	$10.00K	$10.00K
YoY Change	12600.0%	-85.71%	-88.89%
Cash & Equivalents		$7.700K
Short-Term Investments
Other Short-Term Assets	$60.00K	$60.00K	$60.00K
YoY Change	0.0%	-73.91%	-64.71%
Inventory
Prepaid Expenses
Receivables	$30.00K	$12.40K	$10.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.360M	$81.70K	$80.00K
YoY Change	1600.0%	-75.24%	-75.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.00K	$20.00K	$20.00K
YoY Change	0.0%	-33.33%	-33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$23.60K	$20.00K
YoY Change	0.0%	136.0%	100.0%
Total Long-Term Assets	$40.00K	$43.60K	$50.00K
YoY Change	-20.0%	9.0%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$1.360M	$81.70K	$80.00K
Total Long-Term Assets	$40.00K	$43.60K	$50.00K
Total Assets	$1.400M	$125.3K	$130.0K
YoY Change	976.92%	-66.14%	-64.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.490M	$3.087M	$3.090M
YoY Change	-19.42%	77.4%	73.6%
Accrued Expenses	$790.0K	$1.170M	$1.910M
YoY Change	-58.64%	125.0%	193.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$7.390M	$7.390M
YoY Change	-100.0%	73.47%	73.47%
Long-Term Debt Due	$10.00K	$5.200K	$10.00K
YoY Change	0.0%	-48.0%	0.0%
Total Short-Term Liabilities	$3.560M	$13.20M	$13.20M
YoY Change	-73.03%	12.01%	12.05%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$10.00K	$5.000K	$10.00K
YoY Change	0.0%	-50.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.560M	$13.20M	$13.20M
Total Long-Term Liabilities	$10.00K	$5.000K	$10.00K
Total Liabilities	$3.560M	$13.20M	$13.20M
YoY Change	-73.03%	11.96%	11.96%
SHAREHOLDERS EQUITY
Retained Earnings		-$45.64M
YoY Change
Common Stock		$1.900K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.160M	-$13.07M	-$13.07M
YoY Change
Total Liabilities & Shareholders Equity	$1.400M	$125.3K	$130.0K
YoY Change	976.92%	-66.14%	-64.86%

Cashflow Statement

Concept	2013	2012 Q3	2012
OPERATING ACTIVITIES
Net Income	-$10.91M	$4.100M	-$3.407M
YoY Change	220.17%	-251.85%	-61.59%
Depreciation, Depletion And Amortization	$13.00K	$10.00K	$18.80K
YoY Change	-30.85%		88.0%
Cash From Operating Activities	-$3.036M	-$390.0K	-$2.337M
YoY Change	29.92%	-58.51%	-43.96%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$30.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$20.00K	-$20.00K
YoY Change	-100.0%
Cash From Investing Activities	$1.400K	$0.00	-$25.50K
YoY Change	-105.49%		27.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.959M		$900.00
YoY Change	328655.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.322M	400.0K	$2.590M
YoY Change	66.88%	263.64%	-38.62%
NET CHANGE
Cash From Operating Activities	-$3.036M	-390.0K	-$2.337M
Cash From Investing Activities	$1.400K	0.000	-$25.50K
Cash From Financing Activities	$4.322M	400.0K	$2.590M
Net Change In Cash	$1.288M	10.00K	$227.6K
YoY Change	465.73%	-101.2%	658.67%
FREE CASH FLOW
Cash From Operating Activities	-$3.036M	-$390.0K	-$2.337M
Capital Expenditures	$0.00	$30.00K	$0.00
Free Cash Flow	-$3.036M	-$420.0K	-$2.337M
YoY Change	29.92%	-55.32%	-43.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q1	dei	Entity Public Float EntityPublicFloat	6066000	USD
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5900	USD
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	14300	USD
CY2013Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	66700	USD
CY2012Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	260000	USD
CY2013Q3	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	294500	USD
CY2012Q3	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	499100	USD
CY2013Q3	cnso	Accrued Consulting Fees Liability Related Party AccruedConsultingFeesLiabilityRelatedParty	0	USD
CY2012Q3	cnso	Accrued Consulting Fees Liability Related Party AccruedConsultingFeesLiabilityRelatedParty	81000	USD
CY2013Q3	cnso	Subordinated Secured Debt Instrument Unamortized Discount One SubordinatedSecuredDebtInstrumentUnamortizedDiscountOne	0	USD
CY2012Q3	cnso	Subordinated Secured Debt Instrument Unamortized Discount One SubordinatedSecuredDebtInstrumentUnamortizedDiscountOne	416700	USD
CY2013Q3	cnso	Unsecured Debt Instrument Unamortized Discount UnsecuredDebtInstrumentUnamortizedDiscount	0	USD
CY2012Q3	cnso	Unsecured Debt Instrument Unamortized Discount UnsecuredDebtInstrumentUnamortizedDiscount	37500	USD
CY2013Q3	cnso	Unperfected Senior Convertible Promissory Notes Net Of Discount UnperfectedSeniorConvertiblePromissoryNotesNetOfDiscount	0	USD
CY2012Q3	cnso	Unperfected Senior Convertible Promissory Notes Net Of Discount UnperfectedSeniorConvertiblePromissoryNotesNetOfDiscount	370200	USD
CY2013Q3	cnso	Secured Debt Instrument Unamortized Discount SecuredDebtInstrumentUnamortizedDiscount	0	USD
CY2012Q3	cnso	Secured Debt Instrument Unamortized Discount SecuredDebtInstrumentUnamortizedDiscount	0	USD
CY2013Q3	cnso	Liabilities Of Disposal Group Including Discontinued Operation Related Parties Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationRelatedPartiesCurrent	0	USD
CY2012Q3	cnso	Liabilities Of Disposal Group Including Discontinued Operation Related Parties Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationRelatedPartiesCurrent	89000	USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92716562	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1914175	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92716562	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1914175	shares
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1273600	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7700	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26600	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12400	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	63700	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43700	USD
CY2013Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2012Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	17900	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1363900	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	81700	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16800	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21500	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23600	USD
CY2013Q3	us-gaap	Assets Assets	1402200	USD
CY2012Q3	us-gaap	Assets Assets	125300	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2493200	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3086700	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24200	USD
CY2012Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20600	USD
CY2013Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	763100	USD
CY2012Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	732700	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0	USD
CY2012Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	104000	USD
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2012Q3	us-gaap	Interest Payable Current InterestPayableCurrent	1048800	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	6000	USD
CY2012Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6000	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	3562200	USD
CY2012Q3	us-gaap	Liabilities Liabilities	13200000	USD
CY2013	cnso	Product Development ProductDevelopment	1119500	USD
CY2012	cnso	Product Development ProductDevelopment	589200	USD
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	347500	USD
CY2012	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	997100	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2554000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2938100	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	4331500	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	4920900	USD
CY2013Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2012Q3	us-gaap	Notes Payable Current NotesPayableCurrent	200000	USD
CY2013Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2012Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	520700	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	7200	USD
CY2012Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5200	USD
CY2013Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	268500	USD
CY2012Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	288700	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3556200	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13195000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	92700	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	1900	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54298000	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32566700	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56550700	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45643300	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-2160000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-13074700	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1402200	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125300	USD
CY2013	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	130900	USD
CY2012	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	115000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-4200600	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-4805900	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1288200	USD
CY2012	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4123200	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	556300	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	62100	USD
CY2012	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	151500	USD
CY2013	cnso	Offering Costs OfferingCosts	2500	USD
CY2012	cnso	Offering Costs OfferingCosts	784100	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97600	USD
CY2012	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6950300	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6686600	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1891500	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10887200	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2914400	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1900	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10888000	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2916300	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-19400	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-490500	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.55
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.00
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.26
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2013	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.14
CY2012	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.55
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.00
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.26
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75800179	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1887508	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75800179	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1887508	shares
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-10907400	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3406800	USD
CY2013	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	5792500	USD
CY2012	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	-11421500	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1350800	USD
CY2012	cnso	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	900	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1257300	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7900	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1900	USD
CY2012	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	400000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	30400	USD
CY2013	cnso	Stock Issued During Period Value Issued For Lieu Of Cash To Creditors StockIssuedDuringPeriodValueIssuedForLieuOfCashToCreditors	502100	USD
CY2013	cnso	Stock Issued During Period Value Conversion Of Convertible Senior Subordinated Securities StockIssuedDuringPeriodValueConversionOfConvertibleSeniorSubordinatedSecurities	3789200	USD
CY2013	cnso	Stock Issued During Period Value Conversion Of Convertible Subordinated Securities Two StockIssuedDuringPeriodValueConversionOfConvertibleSubordinatedSecuritiesTwo	2301400	USD
CY2013	cnso	Stock Issued During Period Value Conversion Of Convertible Unsecured Securities One StockIssuedDuringPeriodValueConversionOfConvertibleUnsecuredSecuritiesOne	101900	USD
CY2013	cnso	Stock Issued During Period Value Conversion Of Convertible Unsecured Securities Two StockIssuedDuringPeriodValueConversionOfConvertibleUnsecuredSecuritiesTwo	2080000	USD
CY2013	cnso	Stock Issued For Private Placement Shares Purchases StockIssuedForPrivatePlacementSharesPurchases	2958800	USD
CY2013	cnso	Stock Issued During Period Value Conversion Of Convertible Subordinated Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSubordinatedSecuritiesOne	3000600	USD
CY2013	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	13000	USD
CY2012	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	18800	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	662300	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3544200	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1257300	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1350800	USD
CY2013	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	30400	USD
CY2012	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	56800	USD
CY2013	cnso	Noncash Interest Expense NoncashInterestExpense	622200	USD
CY2012	cnso	Noncash Interest Expense NoncashInterestExpense	664300	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14200	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6800	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-63400	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1386300	USD
CY2013	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2012	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	4600	USD
CY2013	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line basis
CY2012	us-gaap	Debt Instrument Interest Rate Effective Percentage Rate Range Maximum DebtInstrumentInterestRateEffectivePercentageRateRangeMaximum	0.09	pure
CY2013Q3	cnso	Debt Conversion Option Liability DebtConversionOptionLiability	0	USD
CY2012Q3	cnso	Warrant Liability WarrantLiability	520700	USD
CY2013Q3	cnso	Warrant And Conversion Derivative Liability Decreased Value WarrantAndConversionDerivativeLiabilityDecreasedValue	0	USD
CY2013	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	97600	USD
CY2012	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	6950300	USD
CY2013	us-gaap	Depreciation Depreciation	13000	USD
CY2012	us-gaap	Depreciation Depreciation	18800	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64800	USD
CY2012Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	50700	USD
CY2013Q3	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	1864700	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	14400	USD
CY2012	us-gaap	Advertising Expense AdvertisingExpense	57400	USD
CY2013	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	As the original conversion terms of the notes were at $1 into one share of common stock with a fair value of $0.25, so the three additional shares offered on conversion at $0.25 each represent the inducement to convert.
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
	cnso	Stock Traded Value StockTradedValue	277636	USD
CY2013	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	30400	USD
CY2012	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3036200	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2337000	USD
CY2013	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	0	USD
CY2012	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	4300	USD
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1400	USD
CY2012	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21200	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1400	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25500	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4700	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6100	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2958800	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	900	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1368300	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2595300	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4322400	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2590100	USD
CY2013	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-21700	USD
CY2012	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-293500	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1265900	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-65900	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73600	USD
CY2013	us-gaap	Interest Paid Net InterestPaidNet	3600	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	9300	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	1900	USD
CY2013	cnso	Offering Costs Cash Flow Noncash Investing And Financing Activities OfferingCostsCashFlowNoncashInvestingAndFinancingActivities	2500	USD
CY2012	cnso	Offering Costs Cash Flow Noncash Investing And Financing Activities OfferingCostsCashFlowNoncashInvestingAndFinancingActivities	784100	USD
CY2013	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	7900	USD
CY2012	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	0	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	502100	USD
CY2012	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1287600	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	227600	USD
CY2013	cnso	Shares Issued On Conversion Of Promissory Notes And Accrued Interest SharesIssuedOnConversionOfPromissoryNotesAndAccruedInterest	11273100	USD
CY2012	cnso	Shares Issued On Conversion Of Promissory Notes And Accrued Interest SharesIssuedOnConversionOfPromissoryNotesAndAccruedInterest	0	USD
CY2013	cnso	Increase Decrease In Accrued Compensation And Others IncreaseDecreaseInAccruedCompensationAndOthers	0	USD
CY2012	cnso	Increase Decrease In Accrued Compensation And Others IncreaseDecreaseInAccruedCompensationAndOthers	469000	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-BOTTOM: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0px" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify"> <td style="WIDTH: 0in"></td> <td style="WIDTH: 0.5in; TEXT-ALIGN: left"> <div><b>1.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>NATURE OF OPERATIONS</b></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"><b>Organization and Nature of Operations</b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">CNS Response, Inc. (the “Company”) was incorporated in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Delaware<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>March 20, 1987,<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> under the name Age Research, Inc.   Prior to January 16, 2007, CNS Response, Inc. (then called Strativation, Inc.) existed as a “shell company” with nominal assets whose sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.  On January 16, 2007, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CNS Response, Inc., a California corporation formed on January 11, 2000 (“CNS California”), and CNS Merger Corporation, a California corporation and the Company’s wholly-owned subsidiary (“MergerCo”) pursuant to which the Company agreed to acquire CNS California in a merger transaction wherein MergerCo would merge with and into CNS California, with CNS California being the surviving corporation (the “Merger”). On March 7, 2007, the Merger closed, CNS California became a wholly-owned subsidiary of the Company, and on the same date the corporate name was changed from Strativation, Inc. to CNS Response, Inc.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">The Company is a clinical decision support company with a patented commercial neurometric platform to predict drug response for treatment of brain disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder (“PTSD”).  The Company has commenced a reimbursed 2,000 patient trial at Walter Reed National Military Medical Center (“Walter Reed”) and Fort Belvoir Community Hospital focused on patients with depression, PTSD and mild traumatic brain injury in order to support clinical decisions in the treatment of depression and related disorders.  We will be reimbursed by Walter Reed at our standard rate for each Psychiatric Electroencephalographic Evaluation Registry (“PEER”) Outcome report rendered in the study.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">In addition, the Company had acquired the Neuro-Therapy Clinic, Inc. (“NTC”) on January 15, 2008, which provided behavioral health care services.  However, due to the Company’s inability to raise sufficient funding and due to NTC’s continued operating losses, it was decided to discontinue the operations of NTC effective September 30, 2012, as the Company chose to focus its limited cash resources on the clinical trial at Walter Reed. NTC is accounted for as a discontinued operation as detailed in <i>Footnote 3</i>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">On April 2, 2012, the Company announced that on March 30, 2012 it had filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) to (i) effect a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>1-for-30<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>reverse stock split (“reverse split”) of its common stock, par value $0.001 per share (the “Common Stock”), effective at 5:00 p.m. Pacific Time on April 2, 2012 (the “Effective Time”), and (ii) simultaneously therewith reduce the number of authorized shares of Common Stock available for issuance under the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750</font> million to 100 million. Because the Amendment did not reduce the number of authorized shares of Common Stock in the same proportion as the reverse split, the effect of the Amendment was to increase the number of shares of Common Stock available for issuance relative to the number of shares issued and outstanding.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">At the Effective Time, immediately and without further action by the Company’s stockholders, every 30 shares of the Company’s Common Stock issued and outstanding immediately prior to the Effective Time were automatically combined into one share of Common Stock. In the event the reverse split left a stockholder with a fraction of a share, the number of shares due to that stockholder was rounded up. Further, any options, warrants and rights outstanding as of the Effective Time that were subject to adjustment were adjusted in accordance with the terms thereof. These adjustments included, without limitation, changes to the number of shares of Common Stock that would be obtained upon exercise or conversion of such securities, and changes to the applicable exercise or purchase price.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">On May 23, 2013, the Company held its 2013 annual meeting of stockholders (the “2013 Annual Meeting”), the holders of the Company’s common stock voted to elect each of the following directors to serve until the next annual meeting and until his successor is elected and qualified: Thomas Tierney, John Pappajohn, Walter Schindler, Zachary McAdoo, Richard Turner, Andrew Sassine and Robert Follman.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At the 2013 Annual Meeting the shareholders also approved the following proposals:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </div> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”) in order to increase the number of shares of common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share, authorized for issuance under the Charter from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000,000</font>.</font></div> </td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To amend the Company’s Charter in order to create one or more new series of preferred stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> per share, and authorize <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of such preferred stock for issuance.</font></div> </td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To adopt the Company’s 2012 Omnibus Incentive Compensation Plan, as amended, to award grants of up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of common stock.</font></div> </td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To consider and provide an advisory (non-binding) vote to approve the compensation of the Company’s named executive officers as described in the proxy statement (the “Say-on-Pay Vote”) and to consider the frequency of holding the Say-on-Pay Vote (with shareholders approving a three year cycle).</font></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-BOTTOM: 0px; MARGIN-LEFT: 0.5in; MARGIN-TOP: 0px"> <font style="FONT-SIZE: 10pt">The Company’s Charter was amended for the first two of these items effective May 31, 2013.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: -0.25in" align="justify">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"><b>Going Concern Uncertainty</b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">The accompanying audited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America which contemplate continuation of the Company as a going concern. The Company has a limited operating history and its operations are subject to certain problems, expenses, difficulties, delays, complications, risks and uncertainties frequently encountered in the operation of a new business. These risks include the ability to obtain adequate financing on a timely basis, the failure to develop or supply technology or services to meet the demands of the marketplace, the failure to attract and retain qualified personnel, competition within the industry, government regulation and the general strength of regional and national economies.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">The Company’s continued operating losses and limited capital raise substantial doubt about its ability to continue as a going concern. The Company has limited cash resources for its operations and will need to raise additional funds to meet its obligations as they become due.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">To date, the Company has financed its cash requirements primarily from debt and equity financings.  It will be necessary for the Company to raise additional funds immediately to continue its operations and to raise substantial additional funds before the Company can increase demand for its PEER Online services (formerly known as rEEG services). Until it can generate a sufficient amount of revenues to finance its cash requirements, which it may never do, the Company has to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The Company’s liquidity and capital requirements depend on several factors, including the rate of market acceptance of its services, the future profitability of the Company, the rate of growth of the Company’s business and other factors described elsewhere in this report.  The Company continues to explore additional sources of capital but there is substantial doubt as to whether any financing arrangement will be available in amounts and on terms acceptable to the Company to permit it to continue operations. The Company was unsuccessful in consummating the public offering of securities it had been pursuing in 2012. The accompanying audited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As of November 30, 2012 the Company closed on a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> million round of convertible debt financing and has approval from the majority of note holders in each tranche to raise an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million of debt. All $2 million of this debt and $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81,800</font> interest thereon was converted to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 44,085,044</font> shares of common stock at $0.25 per share, par value $0.001 per share, between January 18, 2013 and September 30, 2013.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">Between February 22, 2013 and April 4, 2013, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,180,000</font> shares of its common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share, at a per share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font>, in a private placement to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font> accredited investors, including <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000</font> shares issued to two affiliates of the Company, for gross cash proceeds to the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,045,000</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">Between May 10, 2013 and September 12, 2013, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000,000</font> shares of its common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share at a per share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font>, in a private placement to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23</font> accredited investors, including <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,400,000</font> shares issued to three affiliates of the Company, for gross cash proceeds to the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">On August 12, 2013, pursuant to an offer to all holders of debt convertible into common stock at $1.00 per share all holders agreed to convert $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,723,400</font> of convertible debt and interest thereon into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,893,419</font> shares of common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share, at a per share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>0.25<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in" align="justify">The private placements were made pursuant to an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D thereunder, as the shares of common stock were issued to accredited investors, without a view to distribution, and not through any general solicitation or advertisement. The shares of common stock have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	750000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	15000000	shares
CY2013	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Delaware
CY2013	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1987-03-20
CY2012	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-30
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012	cnso	Shares Authorized Reduction Shares SharesAuthorizedReductionShares	100000000	shares
CY2013Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2013Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1023600	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, doubtful accounts, intangible assets, income taxes, valuation of equity instruments, accrued liabilities, contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	793200	USD
CY2011Q3	cnso	Warrants Outstanding WarrantsOutstanding	980390	shares
CY2012Q3	cnso	Warrants Outstanding WarrantsOutstanding	2164440	shares
CY2013	cnso	Warrants Issued Exercise Price WarrantsIssuedExercisePrice	3.03
CY2012	cnso	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	0	shares
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.25
CY2013Q3	cnso	Debt Instrument Conversion Vote Percentage DebtInstrumentConversionVotePercentage	1	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0062	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0079	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	3.8	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	3.93	pure
CY2013Q3	cnso	Total Stock Shares Authorized TotalStockSharesAuthorized	165000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2013Q1	cnso	Common Stock Shares Authorized Increased Number CommonStockSharesAuthorizedIncreasedNumber	150000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2012Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	333334	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	42670	shares
CY2012Q1	cnso	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedExercisePrice	3.00
CY2013	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	15000	USD
	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	36700	USD
CY2013Q1	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	283400	USD
CY2013Q3	cnso	Warrants Outstanding WarrantsOutstanding	1497556	shares
CY2013	cnso	Warrants Forfeited Exercise Price WarrantsForfeitedExercisePrice	3.00
CY2012	cnso	Warrants Surrendered WarrantsSurrendered	2823	shares
CY2012	cnso	Warrants Surrendered Exercise Price WarrantsSurrenderedExercisePrice	0.30
CY2012	cnso	Warrants Expired WarrantsExpired	175195	shares
CY2013	cnso	Warrants Forfeited WarrantsForfeited	1617345	shares
CY2013	cnso	Common Stock Issue Price Per Share CommonStockIssuePricePerShare	0.001
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20125	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2152	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	546746	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.08
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0113	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.74	pure
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.00
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	524201	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	9205000	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	42670	shares
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9749594	shares
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.88
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.00
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.05
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	24.08
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.10
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	11275000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.12	pure
CY2013	cnso	Effective Income Tax Rate Reconciliation Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationExtinguishmentOfDebt	-0.02	pure
CY2012	cnso	Effective Income Tax Rate Reconciliation Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationExtinguishmentOfDebt	0	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.03	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.13	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.09	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.12	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1816254	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3686533	shares
CY2013	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	76448279	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	76488279	shares
CY2013	cnso	Debt Conversion Original Debt Principal Amount DebtConversionOriginalDebtPrincipalAmount	9612100	USD
	cnso	Debt Conversion Original Debt Principal Amount DebtConversionOriginalDebtPrincipalAmount	9613900	USD
CY2013	cnso	Debt Conversion Original Debt Interest Amount DebtConversionOriginalDebtInterestAmount	1661000	USD
	cnso	Debt Conversion Original Debt Interest Amount DebtConversionOriginalDebtInterestAmount	1661100	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	11273100	USD
CY2013Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	33100000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2031-09-30
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.04	pure
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15370600	USD
CY2012Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14037500	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1168300	USD
CY2012Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	2967300	USD
CY2013Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2900	USD
CY2012Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7700	USD
CY2013Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4300	USD
CY2012Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8700	USD
CY2013Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2012Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.03	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.03	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.17	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2013Q3	cnso	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	16546100	USD
CY2012Q3	cnso	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	17021200	USD
CY2013Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16546100	USD
CY2012Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17021200	USD
CY2013Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16546100	USD
CY2012Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17021200	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10907400	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3406800	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10907400	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3406800	USD
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	47600	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	43600	USD
CY2013	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	0	USD
CY2012	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	49900	USD

Files In Submission

Name	View Source	Status
0001144204-13-068769-index-headers.html	Edgar Link	pending
0001144204-13-068769-index.html	Edgar Link	pending
0001144204-13-068769.txt	Edgar Link	pending
0001144204-13-068769-xbrl.zip	Edgar Link	pending
cnso-20130930.xml	Edgar Link	completed
cnso-20130930.xsd	Edgar Link	pending
cnso-20130930_cal.xml	Edgar Link	unprocessable
cnso-20130930_def.xml	Edgar Link	unprocessable
cnso-20130930_lab.xml	Edgar Link	unprocessable
cnso-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v363100_10k.htm	Edgar Link	pending
v363100_ex31-1.htm	Edgar Link	pending
v363100_ex31-2.htm	Edgar Link	pending
v363100_ex32-1.htm	Edgar Link	pending
v363100_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMMA
Emmaus Life Sciences, Inc. Stock $emma

2013 Form 10-K Financial Statement

#000114420413068769 Filed on December 23, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA Emmaus Life Sciences, Inc. Stock $emma

2013 Form 10-K Financial Statement

#000114420413068769 Filed on December 23, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA
Emmaus Life Sciences, Inc. Stock $emma